Sarepta Therapeutics, Inc. - 8-K Filing
Sarepta Therapeutics reports Q3 2026 net product revenues of $323.8 million and raises full-year revenue guidance floor by $50 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SRPT